U.S. Markets closed

Potential Milestones Coming for Kitov Pharma and Product Commercialization Plans

NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Kitov Pharma Ltd. (KTOV), an innovative pharmaceutical drug development company. Kitov's NT219, a novel patented small molecule designed to overcome cancer drug resistance, is currently in pre-clinical development.

The shares of KTOV continue to experience a surge in volumes after the company reported the significant breakthrough of gaining FDA approval for its lead drug candidate, Consensi™, as well as the excellent progress that the company has made in its NT-219 pre-clinical development program during 2018.

See what milestones are expected in 2019, how KTOV may commercialize products and more in our complimentary analyst report READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/ktov/

Kitov is working productively with Coeptis Pharmaceuticals and its outstanding team to launch Consensi™ in the U.S. market to create better patient compliance and improved treatment for people living with osteoarthritis pain and hypertension. Additionally, the management is very satisfied with the on-target execution of its NT-219 oncology program and look forward to initiating clinical trials later this year.

KTOV product progress, analysts view and much more in this comprehensive report READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/ktov/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source

View source version on accesswire.com: